PIK3CA and cancer: For example, the mTOR inhibitors Temsiro-Limus and Everolimus and the PI3K inhibitors Idelalisib and Copanlisib have been accepted by the FDA for Clinical treatment of patients with cancer (Janku et al., 2011; Moulder et al., 2011; Janku et al., 2014).